523 related articles for article (PubMed ID: 27992962)
1. C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody-mediated rejection episode: a retrospective cohort study.
Moktefi A; Parisot J; Desvaux D; Canoui-Poitrine F; Brocheriou I; Peltier J; Audard V; Kofman T; Suberbielle C; Lang P; Rondeau E; Grimbert P; Matignon M
Transpl Int; 2017 Mar; 30(3):277-287. PubMed ID: 27992962
[TBL] [Abstract][Full Text] [Related]
2. Detection of Complement-binding Donor-specific Antibodies, Not IgG-antibody Strength Nor C4d Status, at Antibody-mediated Rejection Diagnosis Is an Independent Predictor of Kidney Graft Failure.
Malheiro J; Santos S; Tafulo S; Dias L; Martins S; Fonseca I; Almeida M; Pedroso S; Beirão I; Castro-Henriques A; Cabrita A
Transplantation; 2018 Nov; 102(11):1943-1954. PubMed ID: 29757900
[TBL] [Abstract][Full Text] [Related]
3. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection.
Yell M; Muth BL; Kaufman DB; Djamali A; Ellis TM
Transplantation; 2015 Jun; 99(6):1151-5. PubMed ID: 25839705
[TBL] [Abstract][Full Text] [Related]
4. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.
Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
Transpl Int; 2017 Apr; 30(4):347-359. PubMed ID: 27717025
[TBL] [Abstract][Full Text] [Related]
5. Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection.
Ali S; Ormsby A; Shah V; Segovia MC; Kantz KL; Skorupski S; Eisenbrey AB; Mahan M; Huang MA
Transpl Immunol; 2012 Jan; 26(1):62-9. PubMed ID: 21907804
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
[TBL] [Abstract][Full Text] [Related]
7. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.
Burbach M; Suberbielle C; Brochériou I; Ridel C; Mesnard L; Dahan K; Rondeau E; Hertig A
Transplantation; 2014 Nov; 98(10):1056-9. PubMed ID: 24839895
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
[TBL] [Abstract][Full Text] [Related]
9. Complement-fixing donor-specific anti-HLA antibodies and kidney allograft failure.
Cazarote HB; Shimakura S; Valdameri JS; Contieri FLC; von Glehn CQC; Aita CM; Susin MF; Sotomaior VS; Glehn-Ponsirenas R
Transpl Immunol; 2018 Aug; 49():33-38. PubMed ID: 29596992
[TBL] [Abstract][Full Text] [Related]
10. Use of complement binding assays to assess the efficacy of antibody mediated rejection therapy and prediction of graft survival in kidney transplantation.
Ramon DS; Huang Y; Zhao L; Rendulic T; Park JM; Sung RS; Samaniego M
Hum Immunol; 2017 Feb; 78(2):57-63. PubMed ID: 27894836
[TBL] [Abstract][Full Text] [Related]
11. C4D deposition and positive posttransplant crossmatch are not necessarily markers of antibody-mediated rejection in renal allograft recipients.
Banasik M; Boratyńska M; Nowakowska B; Haloń A; Kościelska-Kasprzak K; Drulis-Fajdasz D; Patrzałek D; Weyde W; Klinger M
Transplant Proc; 2007 Nov; 39(9):2718-20. PubMed ID: 18021967
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pathological analyses of transplant glomerulopathy cases.
Shimizu T; Ishida H; Toki D; Nozaki T; Omoto K; Tanabe K; Honda K; Koike J
Nephrology (Carlton); 2014 Jun; 19 Suppl 3():21-6. PubMed ID: 24842817
[TBL] [Abstract][Full Text] [Related]
13. Correlations between donor-specific antibodies and non-adherence with chronic active antibody-mediated rejection phenotypes and their impact on kidney graft survival.
Malheiro J; Santos S; Tafulo S; Dias L; Martins S; Fonseca I; Almeida M; Pedroso S; Beirão I; Castro-Henriques A; Cabrita A
Hum Immunol; 2018 Jun; 79(6):413-423. PubMed ID: 29577962
[TBL] [Abstract][Full Text] [Related]
14. C1q Donor-Specific Antibody Associates with Post-transplant Biopsy Findings in Highly- Sensitized Kidney Transplant Recipients.
Kuppachi S; Holanda D; Gallegos S; Field EH
Clin Transpl; 2016; 32():127-134. PubMed ID: 28564530
[TBL] [Abstract][Full Text] [Related]
15. Relationship among C1q-fixing de novo donor specific antibodies, C4d deposition and renal outcome in transplant glomerulopathy.
Messina M; Ariaudo C; Praticò Barbato L; Beltramo S; Mazzucco G; Amoroso A; Ranghino A; Cantaluppi V; Fop F; Segoloni GP; Biancone L
Transpl Immunol; 2015 Sep; 33(1):7-12. PubMed ID: 26160049
[TBL] [Abstract][Full Text] [Related]
16. Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining.
Akalin E; Dinavahi R; Dikman S; de Boccardo G; Friedlander R; Schroppel B; Sehgal V; Bromberg JS; Heeger P; Murphy B
Clin J Am Soc Nephrol; 2007 Nov; 2(6):1261-7. PubMed ID: 17942771
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation.
Bamoulid J; Roodenburg A; Staeck O; Wu K; Rudolph B; Brakemeier S; Halleck F; Lehner L; Schönemann C; Lachmann N; Budde K
Transplantation; 2017 Sep; 101(9):2165-2174. PubMed ID: 27653301
[TBL] [Abstract][Full Text] [Related]
18. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss.
Sicard A; Ducreux S; Rabeyrin M; Couzi L; McGregor B; Badet L; Scoazec JY; Bachelet T; Lepreux S; Visentin J; Merville P; Fremeaux-Bacchi V; Morelon E; Taupin JL; Dubois V; Thaunat O
J Am Soc Nephrol; 2015 Feb; 26(2):457-67. PubMed ID: 25125383
[TBL] [Abstract][Full Text] [Related]
19. Pre-transplant soluble CD30 in combination with total DSA but not pre-transplant C1q-DSA predicts antibody-mediated graft loss in presensitized high-risk kidney transplant recipients.
Schaefer SM; Süsal C; Opelz G; Döhler B; Becker LE; Klein K; Sickmüller S; Waldherr R; Macher-Goeppinger S; Schemmer P; Beimler J; Zeier M; Morath C
HLA; 2016 Feb; 87(2):89-99. PubMed ID: 26840927
[TBL] [Abstract][Full Text] [Related]
20. Antibody-mediated allograft rejection: morphologic spectrum and serologic correlations in surveillance and for cause biopsies.
Papadimitriou JC; Drachenberg CB; Ramos E; Kukuruga D; Klassen DK; Ugarte R; Nogueira J; Cangro C; Weir MR; Haririan A
Transplantation; 2013 Jan; 95(1):128-36. PubMed ID: 23222897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
